南微医学公告，公司拟以3000万元-5000万元资金回购股份，回购价格不超过96.54元/股。本次回购股份 将全部用于员工持股计划或股权激励，并在回购实施结果暨股份变动公告日后三年内转让。若回购股份 在三年内未能转让完毕，将依法履行减少注册资本的程序，未转让股份将被注销。回购期限为董事会审 议通过之日起6个月内，资金来源为公司自有资金或中信银行南京分行提供的专项贷款。 ...

扫码添加梧桐小师弟 免费领取电子资料 Hello, 这是上交所发布的并购资 料集，保存压缩包到电脑解压即可 a 上交所: 并购一本通 +典型案...30例）.zip 16.02MB 《上市公司并购重组典型案例汇编(30例)》 《并购重组规则、政策与案例一本通 上交所《上市公司并购重组典型案例汇编(30 ... PDF 01.青岛海尔多次产业并购实现跨越式发展 02.产业整合：沃尔德差异化对价购买鑫金泉 昊华科技实施同一控制下产业整合案例 04.持续注入优质资产:长江电力收购水电资产 DF 05.普源精电:提前锁定+分步实施 06.南微医学收购CME: 拓宽海外渠道,加速... 07.大股东注资型产业整合：中直股份收购直升 ... 08.中文传媒：发行股份及支付现金购买资产 PDF 09.跨界并购:安孚科技收购南孚电池 10.小额快速:长岭液压收购江阴尚驰 11.士兰微收购亏损子公司少数股权 12.定向可转债: 思瑞浦收购创芯微 13.定向可转债:华电国际购买少数股权 14.境外收购：闻泰科技收购安世半导体 15.洛阳铝业：多次重大资产购买 17.首旅酒店收购如家酒店集团,打造全国领先 ... 16.长电科技要 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-009 南微医学科技股份有限公司 关于收到董事长提议回购公司股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南微医学科技股份有限公司（以下简称"公司"）于 2025年4月14日收 到公司董事长隆晓辉先生《关于提议南微医学科技股份有限公司以集中竞 价交易方式回购公司社会公众股股份的函》。提议内容主要如下： 一、提议回购股份的原因和目的 为有效维护广大股东利益，增强投资者信心，切实提高公司股东的投 资回报，使公司股价与公司价值相匹配，并基于对公司未来发展的信心和对 公司价值的认可，为进一步建立、健全公司长效激励机制，吸引和留住优秀 人才，充分调动公司员工的积极性和创造性，并增强投资者对公司的投资信 心，紧密结合公司利益、股东利益与员工利益，促进公司健康可持续发展， 结合公司经营情况及财务状况等因素，根据相关法律法规，隆晓辉先生提议 公司以集中竞价交易方式回购部分社会公众股份。 二、提议内容 1.回购股份的种类及方式：通过上海证券交易所股票交易系统 ...

南微医学公告，公司于2025年4月14日收到董事长隆晓辉先生《关于提议南微医学科技股份有限公司以 集中竞价交易方式回购公司社会公众股股份的函》。提议内容主要如下：回购股份的种类及方式为通过 上海证券交易所股票交易系统以集中竞价交易方式回购公司已发行的人民币普通股(A股)股票；回购股 份的用途为股权激励或员工持股计划；回购资金总额不低于人民币3000万元(含)，不超过人民币5000万 元(含)；回购股份的价格不超过董事会通过回购股份决议前30个交易日公司股票交易均价的150%；回购 资金来源为公司自有资金。 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-008 南微医学科技股份有限公司 关于收到《无效宣告请求审查决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 公司于2025年4月3日收到中华人民共和国国家知识产权局（以下简称"国家知 识产权局"）出具的《无效宣告请求审查决定书》（第586612号）。国家知识产权 局对北京中科盛康科技有限公司（以下简称"中科盛康"）提出的有关公司所持有 的"一种止血夹"发明专利无效宣告请求进行了审查。现将有关情况公告如下： 一、本次事项的基本情况 无效宣告请求审查结果：中华人民共和国国家知识产权局经审查决定，在 南微医学科技股份有限公司（以下简称"公司"）于2020年11月10日提交 的 权 利 要 求 1-8 基 础 上 维 持 公 司 的 " 一 种 止 血 夹 " （ 专 利 号 ： 201410222753.7）发明专利权有效。 公司所处的当事人地位：专利权人 是否会对公司损益产生负面影响：本次无效宣告事项不会对公司的日常生 产经营产生负 ...

扫码添加梧桐小师弟 免费领取电子资料 Hello, 这是上交所发布的并购资 料集，保存压缩包到电脑解压即可 a 上交所: 并购一本通 +典型案...30例）.zip 16.02MB 《上市公司并购重组典型案例汇编(30例)》 《并购重组规则、政策与案例一本通 上交所《上市公司并购重组典型案例汇编(30 ... PDF 01.青岛海尔多次产业并购实现跨越式发展 02.产业整合：沃尔德差异化对价购买鑫金泉 昊华科技实施同一控制下产业整合案例 04.持续注入优质资产:长江电力收购水电资产 DF 05.普源精电:提前锁定+分步实施 06.南微医学收购CME: 拓宽海外渠道,加速... 07.大股东注资型产业整合：中直股份收购直升 ... 08.中文传媒：发行股份及支付现金购买资产 PDF 09.跨界并购:安孚科技收购南孚电池 10.小额快速:长岭液压收购江阴尚驰 11.士兰微收购亏损子公司少数股权 12.定向可转债: 思瑞浦收购创芯微 13.定向可转债:华电国际购买少数股权 14.境外收购：闻泰科技收购安世半导体 15.洛阳铝业：多次重大资产购买 17.首旅酒店收购如家酒店集团,打造全国领先 ... 16.长电科技要 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 performance met expectations, with total revenue of 2.76 billion yuan (up 14.47% year-on-year) and net profit attributable to shareholders of 551.67 million yuan (up 13.53% year-on-year) [7] - The company is expanding its overseas presence through strategic acquisitions and partnerships, including the acquisition of a 51% stake in Creo Medical, which will enhance its sales network in Europe [7] - The establishment of a manufacturing center in Thailand is expected to boost production capabilities and support international market expansion [7] - Profit forecasts for 2024-2026 have been adjusted, with net profits projected at 5.52 billion yuan for 2024, 6.97 billion yuan for 2025, and 9.36 billion yuan for 2026, reflecting the company's leading position in overseas market expansion [7] Financial Summary - Total revenue for 2024 is projected at 2.76 billion yuan, with a year-on-year growth rate of 14.47% [1] - Net profit attributable to shareholders for 2024 is expected to be 551.67 million yuan, with a growth rate of 13.53% [1] - The company's earnings per share (EPS) is forecasted to be 2.94 yuan for 2024, with a price-to-earnings (P/E) ratio of 23.89 [1] - The company maintains a healthy financial position with a debt-to-asset ratio of 16.74% and a projected return on equity (ROE) of 13.76% for 2024 [6][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's 2024 performance met expectations, with total revenue of 2.76 billion yuan (up 14.47% year-on-year) and net profit attributable to shareholders of 551.67 million yuan (up 13.53% year-on-year) [7] - The company is expanding its overseas presence through strategic acquisitions and partnerships, including the acquisition of a 51% stake in Creo Medical, which will enhance its sales network in Europe [7] - The establishment of a manufacturing center in Thailand is expected to boost production capabilities and support international market expansion [7] - Profit forecasts for 2024-2026 have been adjusted, with net profits projected at 5.52 billion yuan for 2024, 6.97 billion yuan for 2025, and 9.36 billion yuan for 2026, reflecting the company's leading position in overseas market expansion [7] Financial Summary - Total revenue is projected to grow from 2.41 billion yuan in 2023 to 3.93 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 18.94% [8] - Net profit attributable to shareholders is expected to increase from 486 million yuan in 2023 to 936 million yuan in 2026, with a CAGR of approximately 34.30% [8] - The company's earnings per share (EPS) is forecasted to rise from 2.59 yuan in 2024 to 4.98 yuan in 2026 [8] - The price-to-earnings (P/E) ratio is projected to decrease from 27.12 in 2023 to 14.08 in 2026, indicating potential value appreciation [8]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [2][10]. Core Insights - The company is projected to achieve a revenue of 2.761 billion RMB in 2024, representing a year-on-year growth of 14%. The net profit attributable to shareholders is expected to be 552 million RMB, also up 14% year-on-year [1]. - The company is expanding its overseas market presence and enhancing its production capabilities with the establishment of a manufacturing center in Thailand, which will improve its risk resilience and production capacity for high-end medical devices [1]. - The acquisition of a 51% stake in Creo Medical S.L.U. will strengthen the company's position in the European market, particularly in the minimally invasive surgical equipment sector, and enhance its international sales network [2]. Summary by Sections Performance Overview - For 2024, the company anticipates a revenue of 2.761 billion RMB, a 14% increase from the previous year, and a net profit of 552 million RMB, also reflecting a 14% growth [1]. - In Q4 alone, the expected revenue is 748 million RMB, with a net profit of 101 million RMB, showing a 1% increase year-on-year [1]. Operational Analysis - The company is focusing on independent research and development, innovation in medical technology, and collaboration with academic institutions to deepen its domestic marketing and expand its overseas channels [1]. - The new manufacturing center in Thailand will be equipped with advanced technology and is expected to supply products primarily to the US, Europe, and Southeast Asia [1]. Mergers and Acquisitions - The company plans to acquire 51% of Creo Medical S.L.U. for up to 36.72 million euros, which will enhance its product offerings in Europe and complement its sales channels [2]. Profit Forecast and Valuation - The projected net profits for 2024, 2025, and 2026 are 552 million RMB, 696 million RMB, and 858 million RMB, respectively, with growth rates of 14%, 26%, and 23% [2]. - The current price-to-earnings (P/E) ratios are expected to be 23, 18, and 15 for the years 2024, 2025, and 2026 [2].

Financial Performance - The total operating revenue for 2024 reached RMB 2,760.51 million, an increase of 14.47% compared to the previous year[3] - The net profit attributable to the parent company was RMB 551.67 million, reflecting a growth of 13.53% year-on-year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 542.87 million, up 17.21% from the previous year[3] - The basic earnings per share increased to RMB 2.94, a rise of 13.51% compared to the same period last year[3] - The total assets at the end of the reporting period were RMB 4,759.37 million, an increase of 8.35% from the beginning of the period[3] - The equity attributable to the parent company was RMB 3,831.03 million, which is a 6.07% increase from the beginning of the period[3] - The weighted average return on net assets improved to 14.94%, an increase of 0.69 percentage points year-on-year[3] Strategic Focus - The company continues to focus on independent research and development, medical engineering innovation, and industry-academia collaboration to enhance market presence[6] - The overseas channel coverage has further expanded, indicating a strategic move towards international market growth[6] Risk Awareness - The company emphasizes the importance of risk awareness as the financial data is preliminary and unaudited, urging investors to consider investment risks[7]